Last updated on June 2016

Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes


Brief description of study

Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes

Detailed Study Description

To confirm the effect of treatment with meal-time faster-acting insulin aspart in terms of glycaemic control by comparing it to meal-time NovoRapid®, both in combination with insulin degludec using a non-inferiority approach in children and adolescents with type 1 diabetes.

Clinical Study Identifier: TX144138

Contact Investigators or Research Sites near you

Start Over

Danielle Henson

University of South Florida -Morsani Center for Advanced Healthcare
Tampa, FL USA
  Connect »